If a health plan stops covering U‑200 insulin (200 units/mL), what U‑100 insulin alternative (e.g., insulin lispro [Humalog], insulin aspart [Novolog], insulin glulisine [Apidra]) should be used?

Switch to U-100 Insulin Lispro, Aspart, or Glulisine

If your health plan no longer covers U-200 insulin lispro (Humalog U-200), switch to the U-100 formulation of the same rapid-acting insulin analog—either insulin lispro U-100, insulin aspart U-100 (Novolog), or insulin glulisine U-100 (Apidra)—with appropriate dose conversion. 1, 2

Understanding U-200 vs U-100 Insulin

U-200 insulin lispro contains twice the concentration (200 units/mL) compared to U-100 formulations (100 units/mL). The U-200 formulation was developed specifically for patients requiring large insulin doses to reduce injection volume and improve adherence 1, 3. Importantly, U-200 insulin lispro is bioequivalent to U-100 insulin lispro—meaning the pharmacokinetics and pharmacodynamics are essentially identical 4, 5.

Conversion Strategy

Direct Unit-for-Unit Conversion

• The total number of units remains the same when switching from U-200 to U-100 insulin lispro 3, 4
• If a patient takes 30 units of U-200 lispro before meals, they take 30 units of U-100 lispro
• The only difference is injection volume: 30 units requires 0.15 mL of U-200 but 0.3 mL of U-100

Critical Safety Considerations

• Never use a syringe to withdraw insulin from U-200 pens—this can cause severe overdose 3
• When switching to U-100, patients must use U-100 syringes or U-100 pens
• Verify the insulin concentration on every vial/pen before each injection 3

Alternative Rapid-Acting Insulin Options

If switching insulin types (not just concentration), all three rapid-acting analogs are clinically equivalent 1:

Insulin Lispro U-100 (Humalog)

• First choice: Same molecule as U-200, just different concentration
• Bioequivalent pharmacokinetics—no dose adjustment needed 4
• Available in vials, cartridges, and prefilled pens 3

Insulin Aspart U-100 (Novolog)

• Comparable efficacy and safety to lispro 6, 7, 8
• Similar onset (5 minutes), peak (1-2 hours), duration (3-4 hours) 1
• Interchangeable with lispro in clinical practice 7

Insulin Glulisine U-100 (Apidra)

• Also a rapid-acting analog with similar pharmacokinetics 1
• Equally effective for prandial glucose control 8

Cost Considerations

Prioritize the most affordable option when all are therapeutically equivalent 1:

• Authorized generics of insulin lispro are available at approximately 50% of brand-name cost 9, 10
• Human regular insulin (U-100) is the least expensive alternative but has slower onset (15 minutes vs 5 minutes) and longer duration (6-8 hours vs 3-4 hours), making it suboptimal for prandial coverage 1, 11, 1
• Check manufacturer copay assistance programs: Eli Lilly ($35/month), Novo Nordisk (My$99Insulin), and Sanofi (ValYou $99) 9

Dosing Principles for Rapid-Acting Insulins

All rapid-acting analogs should be administered 1, 2:

• Within 15 minutes before or immediately after meals 3
• Starting dose: 4 units per meal, 0.1 units/kg per meal, or 10% of basal insulin dose per meal 1
• Rotate injection sites (abdomen, buttocks, thighs, upper arms) to prevent lipodystrophy 3

Common Pitfalls to Avoid

1. Concentration confusion: U-200 pens deliver the correct number of units but contain twice the concentration—never attempt dose conversion calculations when switching from U-200 to U-100 of the same insulin 5

2. Syringe mismatch: Using U-100 syringes with U-200 insulin (or vice versa) causes dangerous dosing errors 1

3. Assuming all insulins are interchangeable: While rapid-acting analogs are clinically equivalent, regular human insulin is NOT a suitable substitute due to different pharmacokinetics requiring administration 30 minutes before meals 1, 12

4. Forgetting to adjust basal insulin: When initiating or intensifying prandial insulin, consider reducing basal insulin by the same amount as the starting mealtime dose to prevent hypoglycemia 1

When Rapid-Acting Analogs Are Preferred Over Regular Insulin

The guidelines consistently emphasize that rapid-acting insulin analogs (lispro, aspart, glulisine) are preferred over regular human insulin for prandial coverage because 1, 12:

• Quick onset allows dosing at mealtime rather than 30 minutes before
• Better postprandial glucose control
• Lower hypoglycemia risk
• Greater meal flexibility

Regular insulin should only be considered when cost is prohibitive, despite its suboptimal pharmacodynamic profile 1.